TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02279589

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23® 0,1
Description: Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23® 0,1
Description: Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23® 0,1
Description: Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
Study: NCT02262273

Intervention type: OTHER
Intervention: Data Collection
Description: Colleciton of data from medical records only
Study: NCT01574495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Error Augmentation
Description: error augmentation for arm motor recovery in individuals with stroke

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Error Augmentation
Description: error augmentation for arm motor recovery in individuals with stroke
Study: NCT02364271

Intervention type: OTHER
Intervention: Thrombolysis in myocardial infarction score
Description: An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
Study: NCT02279589

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13® 0,5
Description: The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13® 0,5
Description: The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13® 0,5
Description: The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13® 0,5
Description: The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197).
Study: NCT03120338

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The Development and Wellbeing Assessment
Description: The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
Study: NCT00317941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaferon/Betaseron
Description: 250ug administrated with Betaject

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif
Description: 44ug administered with Rebiject II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaferon/Betaseron
Description: 250ug administrated with Betaject light
Study: NCT02364271

Intervention type: OTHER
Intervention: Thrombolysis in myocardial infarction score
Description: An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.

Intervention type: BIOLOGICAL
Intervention: routine blood test for hs-cTnT
Description: Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.

Intervention type: BIOLOGICAL
Intervention: routine blood test for hs-cTnT
Description: Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.

Intervention type: OTHER
Intervention: HEART score
Description: The modified HEART score of each patient was determined retrospectively by a research assistant.

Intervention type: OTHER
Intervention: HEART score
Description: The modified HEART score of each patient was determined retrospectively by a research assistant.
Study: NCT03004677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous skin-to-skin contact
Description: Infants will rest in skin-to-skin contact on parents' chest 24 hours a day alternating between the parents. The parents will note who provides the SSC and if and for how long they are off SSC for any reason.
Study: NCT03335241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Pegylated liposomal doxorubicin 50mg/m2 iv every 4 weeks
Study: NCT00112437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 3 mg, once weekly for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 10 mg, once weekly for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 25 mg, once weekly for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 50 mg, once weekly for 24 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, two 2800 IU weekly throughout the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, two 2800 IU weekly throughout the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, two 2800 IU weekly throughout the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, two 2800 IU weekly throughout the study

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3, two 2800 IU weekly throughout the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
Study: NCT01949493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical traction
Description: Twelve treatments with mechanical traction using the Phystrac traction apparatus. The Phystrac provides traction to the wrist using weights between 1 and 18 kg. The weights provide a pulling force in line with the forearm. After 8 seconds the weight is lifted, and there is a rest period of 4 seconds. This cycle will be repeated 10 times. Another two sets of 10 traction movements will be applied with the wrist positioned in 30 degrees supination and 30 degrees pronation. In total, 30 traction movements will be applied during each treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual
Description: Usual care provided by the neurologist (e.g. corticosteroid injection, wrist splint, carpal tunnel release surgery).
Study: NCT01512368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercising
Description: A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks.
Study: NCT01810367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX Combined With Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Combined With Cisplatin
Study: NCT02927171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents
Description: Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
Study: NCT02385695

Intervention type: PROCEDURE
Intervention: Posterior Dynamic Stabilization

Intervention type: PROCEDURE
Intervention: Internal Fixation and Fusion
Study: NCT01347918

Intervention type: DEVICE
Intervention: 19F capsule
Description: Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.

Intervention type: DEVICE
Intervention: 19F capsule
Description: Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.

Intervention type: DIETARY_SUPPLEMENT
Intervention: sterculia
Description: 7g of sterculia will be ingested over one week together with the normal breakfast.

Intervention type: DIETARY_SUPPLEMENT
Intervention: sterculia
Description: 7g of sterculia will be ingested over one week together with the normal breakfast.
Study: NCT01750476

Intervention type: DRUG
Intervention: Mirena

Intervention type: DRUG
Intervention: Oral contraception

Intervention type: DRUG
Intervention: Depo-Provera
Study: NCT02250040

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Physiotherapy techniques that included muscle training, stretching and endurance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Physiotherapy techniques that included muscle training, stretching and endurance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Techniques based on patients' functional level were added.
Description: The added techniques aimed to improve balance and movement dissociation.
Study: NCT01635933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens with color
Description: Silicone hydrogel contact lens with color.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phemfilcon A contact lens with color
Description: Hydrogel contact lens with color.
Study: NCT00231985

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habit reversal therapy
Description: Habit reversal therapy consists of awareness training, relaxation training, self-monitoring, and competing response training.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive therapy
Description: Supportive therapy focuses on educating participants about tics: how tics present themselves, the causes of tics, the common conditions that may occur along with tics, and environmental factors that may affect their tics (e.g. family, social, school, stress).
Study: NCT03869138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual-reality based dance training
Description: Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists.
Study: NCT01479790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeGiene
Description: The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
Study: NCT02876224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
Study: NCT00112437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
Study: NCT02876224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
Study: NCT02242149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein
Description: All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Diacerein
Study: NCT02518178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NFC Necklace

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NFC Necklace
Study: NCT06782204

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have blood and urine samples collected 2 hours after administration.
Study: NCT02518178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice Reminder
Description: Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NFC Sticker
Description: NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
Study: NCT02948192

Intervention type: OTHER
Intervention: Survey, Sample collection
Description: Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.

Intervention type: OTHER
Intervention: Survey, Sample collection
Description: Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
Study: NCT04195074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
Study: NCT00417612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pill
Study: NCT02749370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
Study: NCT03897712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Samfilcon B Contact Lenses
Description: Contact lens

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Alden Optical HP Sphere Contact Lens
Description: Hioxifilcon D, 54% water, Alden Optical HP Sphere lens

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ReNu MultiPlus Lubricating and Rewetting Drops
Description: For use as needed during the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReNu MultiPlus Lubricating and Rewetting Drops
Description: For use as needed during the study.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Biotrue Multi-Purpose Solution
Description: For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotrue Multi-Purpose Solution
Description: For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
Study: NCT02203838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: 120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner.
Study: NCT03469245

Intervention type: OTHER
Intervention: numerical simulation
Description: After patients have been treated by fenestrated endovascular of society Vascutek data will be collected by society Vascutek and send to Predisurge society. They will perform numerical simulation and compare with the method of Vascutek.
Study: NCT03207256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: Oral Daily TGR-1202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202 + Ublituximab
Description: Oral Daily TGR-1202 + Ublituximab IV Administration
Study: NCT02226614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: University of Edinburgh head cooling device
Description: head cooling
Study: NCT00112437

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
Study: NCT01215721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesicare
Description: 5 mg daily
Study: NCT04604938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: administration of losartan (50 mg) (oral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: administration of placebo (oral)
Study: NCT00180401

Intervention type: BEHAVIORAL
Intervention: CRT-P and CRT-D devices

Intervention type: BEHAVIORAL
Intervention: CRT-P and CRT-D devices
Study: NCT03671343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Description: It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.
Study: NCT03955276

Intervention type: OTHER
Intervention: Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)
Description: Biologically targeted matched treatment (chosen by treating physician)